Skip to main content
    T

    TuHURA Biosciences Inc (HURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.33
    -0.06 (-4.32%)

    Market Cap: $88.58M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TuHURA Biosciences Inc (HURA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    TuHURA Biosciences reported revenue of $0 for the fiscal year ended Jun 30, 2026. That year, net income was -$30.06M, operating cash flow was -$27.63M and free cash flow was -$27.71M. The quarter ended Sep 30, 2026 had net income of -$6.41M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Jun 2026, with an operating loss of $31.80M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Jun 2026$0N/AN/AN/AN/A
    Jun 2025$0N/AN/AN/AN/A
    Jun 2024$0N/AN/AN/AN/A
    Jun 2023$0N/AN/AN/AN/A
    Jun 2022$0N/AN/AN/AN/A
    Jun 2021N/AN/AN/AN/AN/A
    Jun 2020N/AN/AN/AN/AN/A
    Jun 2019N/AN/AN/AN/AN/A
    Jun 2018N/AN/AN/AN/AN/A
    Jun 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Jun 2017 to Jun 2026

    Income Statement

    In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Cost of revenueN/A$116.71K$55.00K$60.00K$60.00K$32.00K$10.00K$16.35K$24.53K$16.68K
    Gross profitN/A-$116.71K-$55.00K-$60.00K-$60.00K-$32.00K-$10.00K-$16.35K-$24.53K-$16.68K
    Research and development$20.53M$13.34M$2.66M$9.31M$15.17M$11.81M$3.63M$3.66M$7.13M$5.00M
    Operating income-$31.80M-$17.65M-$8.45M-$14.80M-$22.68M-$21.57M-$8.14M-$8.40M-$11.17M-$8.32M
    Net income-$30.06M-$21.68M-$8.32M-$14.65M-$22.66M-$38.30M-$9.13M-$8.05M-$11.14M-$8.08M
    EBITDA-$29.36M-$17.43M-$8.14M-$14.28M-$21.65MN/AN/A-$8.03M-$11.11M-$8.07M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profitN/AN/A-$23.47KN/A-$21.00KN/A-$14.06K-$17.64K-$29.00K-$17.00K-$34.31K-$15.00K
    Operating income-$5.66M-$8.76M-$7.53M-$8.17M-$6.73M-$9.88M-$7.02M-$5.69M-$3.73M-$2.38M-$4.61M-$1.02M
    Net income-$6.41M-$9.22M-$7.54M-$6.77M-$7.10M-$9.52M-$6.66M-$6.00M-$5.58M-$2.32M-$4.84M-$1.02M
    Last 12 quarters

    Balance Sheet

    As of Jun 2026, cash and equivalents exceeded short-term debt of $396.39K by $3.22M.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Total assets$27.35M$19.97M$4.36M$15.20M$6.40M$13.54M$2.94M$4.04M$7.07M$7.91M
    Current assets$4.62M$19.61M$4.16M$14.74M$5.68M$11.79M$2.76M$4.03M$7.05M$7.87M
    Cash and equivalents$3.62M$12.66M$3.67M$14.25M$5.55M$10.54M$2.39M$3.72M$5.97M$6.59M
    Total liabilities$6.42M$5.37M$5.92M$2.89M$7.15M$2.96M$2.67M$2.07M$1.64M$1.33M
    Short-term debt$396.39K$159.84K$20.82K$117.48K$644.07KN/AN/AN/AN/AN/A
    Long-term debtN/AN/A$2.32MN/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$20.93M$14.59M-$1.56M$12.30M-$747.82K$10.58M$263.00K$1.97M$5.44M$6.58M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$36.24M$31.75M$29.70M$27.35M$25.70M$34.62M$14.64M$19.97M$4.14M$6.20M$5.79M$1.89M
    Total liabilities$17.29M$13.25M$6.51M$6.42M$8.92M$15.17M$4.78M$5.37M$2.44M$2.44M$11.85M$2.05M
    Cash and equivalents$1.89M$995.98K$6.30M$3.62M$2.70M$8.51M$6.22M$12.66M$3.02M$4.91M$4.46M$658.00K
    Shareholder equity$18.95M$18.50M$23.19M$20.93M$16.78M$19.45M$9.86M$14.59M$1.70M$3.76M-$6.07M-$164.00K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Jun 2026.

    Annual

    Line itemJun 2026Jun 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018Jun 2017
    Operating cash flow-$27.63M-$14.73M-$11.95M-$7.51M-$6.56M-$18.86M-$7.93M-$6.33M-$9.85M-$8.02M
    Capital expenditures$76.08K$57.91K$79.22K$36.28K$3.28K$8.00K$0$5$9.85M$1
    Free cash flow-$27.71M-$14.79M-$12.03M-$7.54M-$6.57M-$18.87M-$7.93M-$6.33M-$19.70M-$8.02M
    Dividends paid$8.36K$0$6.00K$8.00K$8.00K$8.00K$8.00K$8.36K$8.36K$8.36K
    Investing cash flow-$1.34M-$6.05M-$1.30M-$36.28K-$3.28K$964.00KN/AN/A-$12.65K-$20.96K
    Financing cash flow$19.93M$29.77M$2.66M$16.25M$7.04M$26.04M$6.60M$4.07M$9.25M$8.47M
    Fiscal years ended Jun 2017 to Jun 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.01M-$8.63M-$4.41M-$5.56M-$11.09M-$6.25M-$4.74M-$2.60M-$8.69M-$5.07M-$3.83M$2.30M
    Capital expenditures$0$136.98K$48.85K$27.85K$4$5.56K$42.67K$21.40K$16.50K$0$0$20.00K
    Free cash flow-$5.01M-$8.77M-$4.46M-$5.58M-$11.09M-$6.25M-$4.78M-$2.62M-$8.71M-$5.07M-$3.83M$2.28M
    Last 12 quarters

    Frequently Asked Questions About HURA

    What is TuHURA Biosciences' annual revenue?

    TuHURA Biosciences reported revenue of $0 for the fiscal year ended Jun 30, 2026.

    Is TuHURA Biosciences profitable?

    No. TuHURA Biosciences reported net income of -$30.06M for the fiscal year ended Jun 30, 2026.

    How much free cash flow does HURA generate?

    For the fiscal year ended Jun 30, 2026, operating cash flow of -$27.63M minus capital expenditures of $76.08K produced free cash flow of -$27.71M.

    How much debt does TuHURA Biosciences have?

    The balance sheet dated Jun 30, 2026 reported short-term debt of $396.39K and cash and equivalents of $3.62M.